Search

Zentalis Pharmaceuticals Inc

Lezárt

4.88 2.95

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

4.78

Maximum

4.9

Fő mutatók

By Trading Economics

Bevétel

-136K

-35M

Egy részvényre jutó nyereség

-0.503

Munkavállalók

106

EBITDA

2.2M

-35M

Ajánlások

By TipRanks

Ajánlások

Vétel

12 hónapos előrejelzés

+31.15% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. aug. 4.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

41M

336M

Előző nyitás

1.93

Előző zárás

4.88

Zentalis Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. júl. 11. 23:51 UTC

Cryptocurrency declines amid cautious investor sentiment ahead of key inflation data and geopolitical tensions impacting U.S. markets.

2026. júl. 11. 23:51 UTC

Cryptocurrency prices dip amid geopolitical tensions and cautious investor sentiment ahead of key U.S. inflation reports.

2026. júl. 11. 23:51 UTC

U.S. Stocks Rise Amid AI Enthusiasm and Geopolitical Tensions; Key Inflation Data and China's Declining Retail Sales Loom Ahead.

2026. júl. 11. 23:51 UTC

Cryptocurrency market dips as Bitcoin and Ethereum decline, while U.S. stocks rise ahead of key inflation data and China's retail sales forecast shows potential consumer spending weakness.

2026. júl. 11. 23:51 UTC

Mixed sentiment ahead of NAB Business Confidence report release on July 14, amid ongoing economic concerns and geopolitical uncertainties in Australia.

2026. júl. 11. 23:51 UTC

Correlated Moves

Bitcoin is lower during Saturday's session, continuing a decline since Friday's close. Volatility included a session high earlier before pulling back.

2026. júl. 11. 23:41 UTC

U.S. Retail Sales Ex Autos Expected to Decline 0.1% in June Amid Weakening Consumer Spending and Economic Uncertainty

2026. júl. 11. 23:41 UTC

Philadelphia Fed Manufacturing Index Release on July 16, 2026, Amid Cautious Market Sentiment Due to Geopolitical Tensions and Upcoming Economic Data.

2026. júl. 11. 23:41 UTC

U.S. Retail Sales Expected to Rise 0.3% in June Amid Strong Consumer Spending Trends, According to Bank of America Report

2026. júl. 11. 23:31 UTC

Canada's Housing Starts Data for June 2026 Expected at 260K Amid Economic Volatility and Affordability Concerns.

2026. júl. 11. 23:21 UTC

U.S. Core Producer Prices Expected to Rise 0.4% in June Amid Mixed Global Inflation Signals and Economic Uncertainties

2026. júl. 11. 23:21 UTC

Cautious Market Sentiment Ahead of July 15 Release of NY Empire State Manufacturing Index Amid Geopolitical Tensions and Earnings Reports

2026. júl. 11. 23:21 UTC

Producers Price Inflation (PPI) MoM for June 2026 set to release on July 15, with a forecasted increase of 0.2%, influencing potential Federal Reserve interest rate decisions amid ongoing inflation concerns.

2026. júl. 11. 23:11 UTC

Brazil's Retail Sales Report on July 16, 2026, Expected to Show Volatility Amid Economic Uncertainty and Mixed Previous Results.

2026. júl. 11. 23:01 UTC

Investors Cautiously Await U.S. Core Inflation Rate Release Amid Geopolitical Tensions and Earnings Uncertainty

2026. júl. 11. 23:01 UTC

Upcoming U.S. CPI Release on July 14 Sparks Caution Among Investors Amid Inflation Concerns and Geopolitical Tensions

2026. júl. 11. 23:01 UTC

Investors Brace for July 14 CPI Release Amid High Inflation Concerns and Potential Fed Rate Hike

2026. júl. 11. 23:01 UTC

Investors Brace for July CPI Release Amid Inflation Concerns and Market Volatility

2026. júl. 11. 23:01 UTC

US Core Inflation Rate Expected to Rise 0.3% in June Amid Market Caution and Geopolitical Tensions

2026. júl. 11. 23:01 UTC

U.S. Inflation Rate Expected to Decrease Slightly in June Amid Cautious Market Sentiment and Geopolitical Tensions

2026. júl. 11. 23:01 UTC

Correlated Moves

The Dow Jones Index declined during after-market hours, reflecting cumulative weakness since Friday's close amid broader market sentiment.

2026. júl. 11. 22:53 UTC

Australia's Westpac Consumer Confidence Index set for July 14, 2026 release amid optimistic market sentiment following positive employment figures and easing geopolitical tensions.

2026. júl. 11. 22:53 UTC

Australia's Westpac Consumer Confidence report on July 14, 2026, is expected to show improvement amid positive stock market gains and ongoing inflation concerns.

2026. júl. 11. 22:41 UTC

MBA 30-Year Mortgage Rate Release on July 15 Expected to Reflect Ongoing Inflation and Geopolitical Tensions Impacting Market Sentiment.

2026. júl. 11. 22:31 UTC

Brazil's Central Bank to Provide Key Interest Rate Outlook on July 13, Amid Global Inflationary Trends.

2026. júl. 11. 22:31 UTC

Japan's Machinery Orders Expected to Decline by 4.2% in May Amid Mixed Economic Sentiment and Geopolitical Tensions

2026. júl. 11. 22:21 UTC

Singapore's Upcoming GDP Growth Rate Release Sparks Cautious Optimism Amid Regional Market Trends and Global Economic Factors

2026. júl. 11. 21:41 UTC

South Korea's Unemployment Rate Release on July 14 Expected to Show Increase Amid Economic Concerns and Job Losses.

2026. júl. 11. 21:31 UTC

UK Retail Sales Monitor YoY Forecasts 2.9% Growth Amid Mixed Sentiment and Geopolitical Concerns Ahead of July Release

2026. júl. 11. 20:41 UTC

India's June 2026 Inflation Rate Expected at 4.3%, Amid Rising Prices and Geopolitical Concerns

Társak összehasonlítása

Árváltozás

Zentalis Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

31.15% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 6.4 USD  31.15%

Magas 10 USD

Alacsony 4 USD

6 Wall Street elemző 12 hónapos célárain alapulva a(z)Zentalis Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

6 ratings

3

Vétel

3

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat